Co announces the results of a Phase II trial of its oral thrombin receptor antagonist SCH 530348 in a clinical trial session at the annual Scientific Sessions of the American College of Cardiology/i2 ...
NEW YORK, Oct 22 (Reuters) - Schering-Plough Corp on Monday said its experimental anti-clotting drug, as in an earlier trial, met its main goal in two additional mid-stage trials of not increasing ...
New Orleans, LA - A novel oral antiplatelet agent has shown promising results in a phase 2 trial in patients undergoing elective stenting, showing a trend toward fewer ischemic events without ...
November 13, 2011 (Orlando, Florida) — A novel oral antithrombotic agent, given to high-risk patients with non-ST-elevation ACS who were mostly already on dual-agent antiplatelet therapy, failed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback